Episode
Psilocybin-Assisted Group Therapy for Depression with Matthew Hicks, ND, MS
- Published
- Oct 29, 2025
- Duration seconds
- 2316
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/psychedelic-medicine-podcast-with-dr-lynn-marie-morski-835820/episodes/psilocybin-assisted-group-therapy-for-depression-with-matthew-hicks-nd-ms/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/psychedelic-medicine-podcast-with-dr-lynn-marie-morski-835820/psilocybin-assisted-group-therapy-for-depression-with-matthew-hicks-nd-ms.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode Matthew Hicks, ND, MS joins to dive into the topic of psilocybin-assisted group therapy for depression. Dr. Hicks is a research Investigator at the National University of Natural Medicine as well as a Naturopathic doctor and licensed psilocybin facilitator at Synaptic Institute. In this conversation, Dr. Hicks shares findings from one of the first studies investigating psilocybin-assisted group therapy for depression, conducted in Oregon's new legal psilocybin framework. He explains how the high cost and labor-intensive nature of psychedelic therapy inspired him to explore a group model that could make treatment more financially accessible while preserving - and even enhancing - its therapeutic potential. Dr. Hicks describes the structure of the study and discusses how initial participant hesitancy about group work transformed into deep connection and shared healing. He also highlights the study's significant reductions in depression scores, improvements across quality-of-life measures, and the potential for group-based approaches to pave the way toward insurance reimbursement and broader access to psychedelic care. In this episode, you'll hear: Why affordability and accessibility were central motivations for developing a group-based psilocybin protocol The benefits and challenges of conducting psilocybin sessions in a shared group setting How Dr. Hicks' study balanced inclusion of low-income participants with safety and stability criteria The details of the group treatment structure for Dr. Hicks' study Why Dr. Hicks believes group formats may be inherently therapeutic in addition to their economic efficiency Dr. Hicks's vision for future efficacy and cost-effectiveness studies that could enable insurance coverage Quotes: "In terms of the group dynamic…